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a b s t r a c t
Hemophagocytic lymphohistiocytosis (HLH) is an inﬂammatory disorder arising from
defects in critical regulatory pathways responsible for termination of inﬂammatory re-
sponse.
We are presenting a case report of a 20-year-old male, admitted to the Department of
Neurology because of left lower limb weakness and balance disturbances. After a few days of
hospitalization, fever occurred. Laboratory tests revealed anemia, neutropenia, lymphope-
nia, and thrombocytopenia. The clinical course and laboratory tests results conﬁrmed the
diagnosis of HLH. In our opinion, the disorder in the presented case occurred due to severe
chronic active Epstein–Barr virus infection syndrome. We are presenting the case of pure
neurological onset of hemophagocytic lymphohistiocytosis in an adult patient.
Hemophagocytic lymphohistiocytosis, initially presenting with neurological symptoms,
can occur in adult patients with irrelevant family history. It is a life-threatening but
potentially curable condition requiring proper diagnostic and treatment management.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Hemophagocytic lymphohistiocytosis (HLH) is an inﬂamma-
tory disorder arising from defects in critical regulatory path-
ways responsible for termination of inﬂammatory response.
The disease leads to a multisystem inﬂammation and organ
inﬁltration. HLH is a rare disorder affecting mostly young
children, but also occurs in adult patients with an incidence
proportion estimated at approximately 1/1,000,000/per year* Corresponding author at: Department of Neurology, Jagiellonian Uni
Tel.: +48 93 57 77 67; fax: +48 12 24 86 26.
E-mail address: kamilaanna@op.pl (&.-W. Kamila).
http://dx.doi.org/10.1016/j.pjnns.2015.07.001
0028-3843/# 2015 Polish Neurological Society. Published by Elsevier S[1]. Neurological onset may be observed in up to 20% of the
cases in children [2]. HLH is a medical condition of immediate
death risk.
2. Case report
A 20-year-old male with irrelevant family history was
admitted to the Department of Neurology University Hospital
in Krakow because of left lower limb weakness and balanceversity Medical College, ul. Botaniczna, 31-503 Krakow, Poland.
p. z o.o. All rights reserved.
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underwent mononucleosis. A neurological examination of the
right lower limb paresis revealed ataxia of lower limbs,
proprioceptive disturbances in the right lower limb up to
the ankle joint and a positive Romberg's test. Initial laboratory
tests results did not show any abnormalities.
The brain MRI indicated hyperintensity in subcortical
nuclei of the left hemisphere and in the matter next to the
anterior horn of the right ventricle.
Following a few days of hospitalization, the patient
developed fever of up to 40 8C. Laboratory tests (Table 1)
revealed anemia, neutropenia, lymphopenia, thrombocytope-
nia and subsequent thrombocytosis of 937  103/mL, hyper-
triglyceridemia, high ferritin level and hyponatremia.
Additionally, there were decreased levels of natural killer
(NK) cells activity (1%), increased levels of liver enzymes,
lactate dehydrogenase (LDH) and D-Dimers. In physical
examination, hepatosplenomegaly was noted.
Cerebrospinal ﬂuid examination revealed the following
results: protein 83 mg/dL (20–40 mg/dL), cytosis 23/3; glucose
2.8 (2.2–4.16 mM/L); EBV DNA 1400 copies/ml; serum IgG
antibodies against Epstein–Barr virus (EBV) (EBV anti VCA/
EA IgG TV index 4.29 and EBV anti EBNA IgG TV index 4.49), but
IgM were absent. In the electromyography and the electro-
neurography, attitudes of sensory-motor demyelinating pe-
ripheral polyneuropathy were described. The diagnosis of
chronic EBV infection was determined.
On the 12th day of hospitalization, a massive nasal
hemorrhage occurred and subsequent 20-min episodes of
biocular blindness. The brain MRI performed the following day
revealed no additional abnormalities.Table 1 – Laboratory results.
Parameter Result Unit Reference range
RBC 3.05 106 L–1 4.5–6.5
Hb 8.1 g/L 12–17
Htc 23.4 % 40.0–54.0
Neu 0.8 103/mL 2.4–7.0
Lymph 0.4 103/mL 0.8–4.0
PLT 50 103/mL 125–340
TG 3.3 mM/L <2.26
Sodium 127 mM/L 136–145
Ferritin 1909 mg/L 30–400
ALT 57 U/L 10–41
AST 143 U/L 10–37
LDH 2798 U/L 240–480
CPK 72 U/L 0–190
INR 1.49 0.8–1.2
PT 16.8 seconds 10–14
Fibrynogen 5.0 g/L 1.8–3.5
D-Dimers >35.2 mg/L <0.5
CRP 160 mg/L <5
Abbreviations: RBC – red blood cells; Hb – hemoglobin; Htc –
hematocrit; Neu – neutrophils; Lymph – lymphocytes; PLT –
platelets; TG – triglycerides; ALT – alanine aminotransferase; AST
– aspartate aminotransferase; ALP – alkaline phosphatase; LDH –
lactate dehydrogenase; CPK – creatine phosphokinase; INR –
international normalized ratio; PT – prothrombine time; CRP – c-
reactive protein.Based on the clinical course and laboratory tests results, the
diagnosis of HLH according to HLH criteria established by the
HLH Study Group of the Histiocyte Society was made [1,7]. HLH
in the presented case was, in our opinion, induced by severe
chronic active EBV infection syndrome (SCAEBV). Bone
marrow aspiration has shown histiomonocytoid cells. The
treatment with cyclosporine, etoposide and dexamethasone,
as prescribed in the HLH 2004 protocol, was administrated [7].
The patient was discharged from our department in a good
state, with no abnormalities in laboratory results, and distal
weakness of lower right limb. He was sent to the Hematologi-
cal Department for further treatment.
3. Discussion
We are reporting the case of the pure neurological onset of
hemophagocytic lymphohistiocytosis secondary to severe
chronic active EBV infection syndrome in an adult patient.
The HLH encompasses the inherited hemophagocytic
lymphohistiocytosis affecting young children and secondary
HLH associated with infections (predominantly EBV), auto-
immunological disease (juvenile arthritis) and malignancies
[1]. In a study reported by Park et al., secondary HLH in adults
was 69.6% caused by EBV infection [3]. Mutation in the perforin
gene was the underlying cause of the disease in 20–40% of
familial HLH. Clinical presentation includes high fever,
hepatosplenomegaly, lymphadenopathy, cytopenia, hypertri-
glycerydemia, hypoﬁbrynogemia, hemofagocytosis and hypo-
natremia. The pathogenesis of the disease is due to
impairment in natural killer and cytotoxic T-lymphocyte
cellular cytotoxicity. It is associated with an accumulation
of non-malignant macrophages (histiocytes) and T-lympho-
cytes in lymph nodes, spleen, liver and other organs.
Hemophagocytosis is a classical ﬁnding but not always
demonstrated [1,2].
Diagnostic criteria were established by the Histiocyte
Society. According to HLH-2004 protocol of the Histiocyte
Society, the condition can be successfully controlled with a
combination of etoposide, dexamethasone, and cyclosporine
A [2].
The Epstein–Barr virus infection causes a wide range of
immunological disorders. Severe chronic active EBV infection
syndrome is a serious form of this infection that shows severe
clinical and hematological features associated with high
antibody titers to EBV-related antigens. The SCAEBV infection
syndrome has a high mortality rate, estimated at up to 40%,
because of life-threatening complications such as hemopha-
gocytic lymphohistiocytosis. B-cells are the general site of the
EBV infection. During persisted infection, virus infects T cells
and natural killer cells, leading to hypercytokinemia [4].
Neurological symptoms and signs may be extremely
variable and include seizures, irritability, cranial nerve palsies,
ataxia, hemiplegia or tetraplegia and coma [1,2]. The study
conducted by Horne et al. suggests that 63% of patients with
HLH have neurological symptoms and/or abnormal CSF
ﬁndings at the time of diagnosis. Additionally, children with
abnormal CSF and neurological symptoms fared worse with
higher incidence of neurological sequelae in long-term
survivors and increased risk of mortality. Abnormal CSF bears
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regard to late sequelae and mortality [2].
HLH can lead to demyelinating peripheral polyneuro-
pathy due to the entry of macrophages into Schwann
cell cytoplasm with dissociation of myelin sheaths [5].
The central nervous system may be involved to diffuse
inﬁltration of leptomeninges by lymphocytes and histiocyte
in early stage of advances. In more severe involvement,
inﬁltration extends into the perivascular spaces. In advanced
stages, massive tissue inﬁltration may follow, particularly
affecting the white matter, and may result in perifocal
gliosis, areas of necrosis and demyelination [2,6]. Shinoda
et al. has reported a case of HLH limited to CNS without the
involvement of other systemic organs or inﬂammatory
response [6].
Without treatment, the disease is fatal in 100% of cases. For
HLH associated with EBV infection treated with HLH-2004
protocol, overall survival rates is 55–78% [2,3].
4. Conclusion
Hemophagocytic lymphohistiocytosis, initially presenting
with neurological symptoms, can occur in adult patients with
irrelevant family history. The disease is a life-threatening but
potentially curable condition requiring proper diagnosis and
treatment management.
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